The following are Delgoffe lab and associated publications - feel free to contact for reprints.


original manuscripts

Menk AV, Scharping NE, Rivadeneira DB, Calderon MJ, Watson MJ, Dunstane D, Watkins SC, Delgoffe GM. “4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses.” Journal of Experimental Medicine. 2018 March 6.

Menk AV*, Scharping NE*, Moreci RS, Zeng X, Guy C, Salvatore S, Bae H,
Xie J, Young HA, Wendell SG, Delgoffe GM. "Early TCR Signaling Induces Rapid
Aerobic Glycolysis Enabling Distinct Acute T Cell Effector Functions." Cell Reports. 2018 Feb 6.

Scharping NE*, Menk AV*, Whetstone RD, Zeng X, and Delgoffe GM. "Efficacy of PD-1 blockade immunotherapy is potentiated by metformin-induced reduction of tumor hypoxia." Cancer Immunol Res. 2016 Dec 10.

Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL, and Delgoffe GM. “The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction.” Immunity 2016 Aug 2.

review articles

Rivadeneira DB and Delgoffe GM. "Antitumor T cell reconditioning: improving metabolic fitness for optimal cancer immunotherapy" Clinical Cancer Research 2018 Jan 31.

Scharping NE and Delgoffe GM. "Tumor microenvironment metabolism: a new checkpoint for anti-tumor immunity." Vaccines (Basel) 2016 Dec 6.

Delgoffe GM. "Filling the tank: keeping anti-tumor T cells metabolically fit for the long haul." Cancer Immunol Res. 2016 Dec 4.

Delgoffe GM. "VHL Brings Warburg into the Memory Spotlight." Immunity. 2016 Nov 15;45(5):953-955.

Delgoffe GM and Powell JD. “Feeding an army: the metabolism of T cells in activation, anergy, and exhaustion.” Mol Immunol. 2015 Dec.

collaborative manuscripts

Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi, EA, Shayan G, Horne W, Moskovitz JM, Kolls JK, Sander C, Shuai Y, Normolle DP, Kirkwood JM, Ferris RL, Delgoffe GM, Bruno TC, Workman CJ, and Vignali DAA. “Interferon-gamma drive Treg fragility to promote anti-tumor immunity. Cell. 2017 Jun 1; 169(6); 1130-1141.e11. doi: 10.1016/j.cell.2017.05.005. PMID: 28552348

Downs-Canner S, Berkley S, Delgoffe GM, Edwards R, Curiel T, Odunsi K, Bartlett D, and Obermajer N. “Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumor-associated Treg cells.” Nat Commun. 2017 Mar 14; 8:14649.

Phong B, Avery L, Menk AVDelgoffe GM, Kane LP. "Cutting Edge: Murine Mast Cells Rapidly Modulate Metabolic Pathways Essential for Distinct Effector Functions." J Immunol. 2017 Jan 15;198(2):640-644. doi: 10.4049/jimmunol.1601150. PMID: 27974455

Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, Stelekati E, McLane LM, Paley MA, Delgoffe GM, and Wherry EJ. “Bioenergetic insufficiencies due to metabolic alterations regulated by PD-1 are an early driver of CD8+ T cell exhaustion.” Immunity 2016 Aug 2.

Pollizzi KN, Sun IH, Patel CH, Lo YC, Oh MH, Waickman AT, Tam AJ, Blosser RL, Wen J, Delgoffe GM, Powell JD. “Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8+ T cell differentiation.” Nat Immunol. 2016 Apr 11.

Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, Beres AJ, Vogel P, Workman CJ, Vignali DA. “Interleukin-35 limits anti-tumor immunity.” Immunity. 2016 Feb 16.

greg's previous major papers

Delgoffe GM*, Woo SR*, Turnis ME, Guy CS, Overacre AE, Gravano DM, Bettini ML, Finkelstein DF, Bonnevier J, Vogel P, Workman CJ and Vignali DA. “Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis.” Nature. 2013 Sep 12. doi:10.1038/nature12428

Collison LW*, Delgoffe GM*, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, Murray PJ, Vignali DA. “The composition and signaling of the IL-35 receptor are unconventional.” Nat Immunol. 2012 Feb 5. doi: 10.1038/ni.2227.

Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, Xiao B, Worley PF, and Powell JD. “The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.” Nat Immunol. 2011 Feb 27

Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthew KL, Xiao B, Worley PF, Kozma SC, Powell JD. “The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.” Immunity. 2009 Jun 19; 30(6):832-44

Zheng Y*, Delgoffe GM*, Meyer CF*, Chan W, Powell JD. "Anergic T cells are metabolically anergic." J Immunol. 2009 Oct 19